ReviewThe Korean journal of internal medicine2022
Desensitization for the prevention of drug hypersensitivity reactions.
Review in The Korean journal of internal medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Engineering tolerogenic mRNA-LNPs for allergen-specific immune reprogramming in pollen allergy.Materials today. Bio · 2026Article
- Treating through in pediatric patients: a single-center experience.European journal of pediatrics · 2026Article
- New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report.Clinical and translational allergy · 2026Review
- Outpatient rapid drug desensitisation for chemotherapy and biologic agents: high success rates in a large single-centre cohort study.BMJ supportive & palliative care · 2026Article
- Successful Sequential and Additive Drug Challenge With Rapid Oral Desensitization in Rifampicin-Induced Fever.Respirology case reports · 2026Article
- Drug-induced anaphylaxis: Molecular pathophysiology, diagnosis, and management.Asia Pacific allergy · 2026Article
- Lessons learned from allergen adsorption on engineered nanomaterials: bridging experimental insights and computational technologies.Nanomedicine (London, England) · 2026Review
- A systematic review of the outcomes of desensitization for delayed-type cutaneous adverse reactions induced by antituberculosis drugs.Asia Pacific allergy · 2026Review
- Women hormones and hypersensitivity: allergic diseases in menopause.Frontiers in allergy · 2026Review
- Clinical and Etiopathological Perspective of Vitamin B1 Hypersensitivity and an Example of a Desensitization Protocol.Life (Basel, Switzerland) · 2025Review
- Molecular Crosstalk Between Intrauterine hCG and Endometrial Receptivity: Signalling Pathways, Immune Modulation, and Translational Perspectives in IVF.International journal of molecular sciences · 2025Review
- Successful desensitization in paclitaxel-induced anaphylaxis: The role of skin testing and environmental sensitization.Asia Pacific allergy · 2025Article
- The Expanding Role of Omalizumab: From Food Allergy to Drug Desensitization.International journal of molecular sciences · 2025Review
- Desensitization for Vitamin B12 Hypersensitivity and How to Do It.Biomedicines · 2025Review
- Article
- Successful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review.Asia Pacific allergy · 2024Article
- Article
- DRESS syndrome due to anti-TB drugs: A complex case with successful re-desensitization of group A drugs.Journal of family medicine and primary care · 2024Article
- Single center experience with more than 600 drug desensitization in Colombia.Frontiers in allergy · 2024Article
- A Narrative Review of Adverse Event Detection, Monitoring, and Prevention in Indian Hospitals.Cureus · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug desensitization is the temporary induction of tolerance to a sensitized drug by administering slow increments of the drug, starting from a very small amount to a full therapeutic dose. It can be used as a therapeutic strategy for patients with drug hypersensitivity when no comparable alternatives are available. Desensitization has been recommended for immunoglobulin E (IgE)-mediated immediate hypersensitivity; however, its indications have recently been expanded to include non-IgE-mediated, non-immunological, or delayed T cell-mediated reactions. Currently, the mechanism of desensitization is not fully understood. However, the attenuation of various intracellular signals in target cells is an area of active research, such as high-affinity IgE receptor (FcεRI) internalization, anti-drug IgG4 blocking antibody, altered signaling pathways in mast cells and basophils, and reduced Ca2+ influx. Agents commonly requiring desensitization include antineoplastic agents, antibiotics, antituberculous agents, and aspirin/nonsteroidal antiinflammatory drugs. Various desensitization protocols (rapid or slow, multi-bag or one-bag, with different target doses) have been proposed for each drug. An appropriate protocol should be selected with the appropriate concentration, dosage, dosing interval, and route of administration. In addition, the protocol should be adjusted with consideration of the severity of the initial reaction, the characteristics of the drug itself, as well as the frequency, pattern, and degree of breakthrough reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.